Point72 Hong Kong’s TG Therapeutics TGTX Stock Holding History

Point72 Hong Kong’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,406	Closed	-$103K	–	1529
2022 Q3	$103K	Buy	17,406 +16,944	+3,668%	+$111K	﹤0.01%	1223
2022 Q2	$2K	Buy	+462	New	+$2.88K	﹤0.01%	1795
2022 Q1	–	Sell	-5,186	Closed	-$99K	–	2314
2021 Q4	$99K	Buy	+5,186	New	+$135K	﹤0.01%	1181
2021 Q3	–	Sell	-1,456	Closed	-$56K	–	2427
2021 Q2	$56K	Buy	+1,456	New	+$57.2K	﹤0.01%	1447
2020 Q2	–	Sell	-258	Closed	-$3K	–	1418
2020 Q1	$3K	Sell	258 -1,571	-86%	-$19.8K	﹤0.01%	835
2019 Q4	$20K	Buy	+1,829	New	+$13.9K	﹤0.01%	886
2018 Q4	–	Sell	-3,637	Closed	-$20K	–	1198
2018 Q3	$20K	Buy	+3,637	New	+$41.6K	0.01%	600
2017 Q1	–	Sell	-4,485	Closed	-$21K	–	974
2016 Q4	$21K	Buy	+4,485	New	+$26.3K	0.02%	546

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Hong Kong's TGTX Position: Q4 2022 in Review

Point72 Hong Kong sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 17,406 shares — an estimated $103K sold.

Point72 Hong Kong first reported a position in TGTX in Q4 2016 and held it in 8 quarters. The position peaked at $103K in Q3 2022. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

Point72 Hong Kong reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 17,406 TG Therapeutics shares in Q4 2022, an estimated $103K.
Point72 Hong Kong first reported a position in TG Therapeutics in Q4 2016 and held it in 8 quarters.
Point72 Hong Kong's TG Therapeutics position peaked at $103K in Q3 2022.
198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.